ResMed and Cardiovascular Disease
Studies show that SDB is an independent risk factor for cardiovascular disease, and can place a patient at higher risk for stroke and sudden cardiac death.
SDB is any abnormal respiration during sleep, including snoring, lapses in breathing (apneas) and reduced airflow (hypopneas).
ResMed offers therapy solutions for those suffering from chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), amyotrophic lateral sclerosis (ALS) and respiratory failure.
Compliance and Monitoring
CPAP treatment is only effective if it is used consistently, so the first step toward patient compliance is making a product that patients want to use. We make flow generators that are sleek, quiet and unobtrusive with an intuitive user interface that mimics computers and cell phones, so it is easy for patients to adjust to therapy and continue using it night after night.
At its founding, ResMed had eight employees, AU$1.2 million to grow the business, and limited manufacturing capabilities.
ResMed was founded in 1989 by Dr. Peter Farrell to advance treatment of sleep apnea, a condition that was relatively unknown and unstudied.
ResMed's Growth Strategy
We have identified three horizons for future growth.
ResMed SDB Therapy Solutions
CPAP is the gold standard for treating SDB. CPAP therapy involves a flow generator that gently delivers pressurized air via a mask to keep the upper airway open during sleep. ResMed creates innovative products for SDB that keep the patient comfortable and are easy to use.